AU2018238540B2 - Treatment of lupus using humanized anti-CXCR5 antibodies - Google Patents

Treatment of lupus using humanized anti-CXCR5 antibodies Download PDF

Info

Publication number
AU2018238540B2
AU2018238540B2 AU2018238540A AU2018238540A AU2018238540B2 AU 2018238540 B2 AU2018238540 B2 AU 2018238540B2 AU 2018238540 A AU2018238540 A AU 2018238540A AU 2018238540 A AU2018238540 A AU 2018238540A AU 2018238540 B2 AU2018238540 B2 AU 2018238540B2
Authority
AU
Australia
Prior art keywords
seq
ser
leu
val
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018238540A
Other languages
English (en)
Other versions
AU2018238540A1 (en
Inventor
Roghieh KARIMI ANDERESI
Jeffrey MING
Moshe E. ZILBERSTEIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Priority claimed from PCT/EP2018/057310 external-priority patent/WO2018172465A1/en
Publication of AU2018238540A1 publication Critical patent/AU2018238540A1/en
Application granted granted Critical
Publication of AU2018238540B2 publication Critical patent/AU2018238540B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2018238540A 2017-03-22 2018-03-22 Treatment of lupus using humanized anti-CXCR5 antibodies Active AU2018238540B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762475173P 2017-03-22 2017-03-22
US62/475,173 2017-03-22
EP17306079 2017-08-18
EP17306079.9 2017-08-18
PCT/EP2018/057310 WO2018172465A1 (en) 2017-03-22 2018-03-22 Treatment of lupus using humanized anti-cxcr5 antibodies

Publications (2)

Publication Number Publication Date
AU2018238540A1 AU2018238540A1 (en) 2019-11-07
AU2018238540B2 true AU2018238540B2 (en) 2025-02-27

Family

ID=61827719

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018238540A Active AU2018238540B2 (en) 2017-03-22 2018-03-22 Treatment of lupus using humanized anti-CXCR5 antibodies

Country Status (7)

Country Link
US (1) US20240207397A1 (https=)
EP (1) EP3601344A1 (https=)
JP (3) JP2020514386A (https=)
KR (2) KR20190131068A (https=)
CN (1) CN110662767A (https=)
AU (1) AU2018238540B2 (https=)
IL (2) IL318907A (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023010483A1 (en) * 2021-08-05 2023-02-09 Hifibio (Hk) Limited Anti-human cxcr5 antibody and uses thereof
WO2021216505A1 (en) * 2020-04-21 2021-10-28 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cxcl13 gene

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009032661A1 (en) * 2007-08-29 2009-03-12 Sanofi-Aventis Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
WO2012010582A1 (en) * 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
WO2016028573A1 (en) * 2014-08-22 2016-02-25 Sorrento Therapeutics, Inc. Antigen binding proteins that bind cxcr5

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009032661A1 (en) * 2007-08-29 2009-03-12 Sanofi-Aventis Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
WO2012010582A1 (en) * 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
WO2016028573A1 (en) * 2014-08-22 2016-02-25 Sorrento Therapeutics, Inc. Antigen binding proteins that bind cxcr5

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ClinicalTrials.gov, 3 June 2016, (2016-06-03),Retrieved from the lnternet:URL: https://clinicaltrials.gov/ct2/show/NCT0233181 [retrieved on 2018-05-18] *

Also Published As

Publication number Publication date
IL269419A (en) 2019-11-28
KR20250052493A (ko) 2025-04-18
JP2025087764A (ja) 2025-06-10
IL318907A (en) 2025-04-01
EP3601344A1 (en) 2020-02-05
JP2023040241A (ja) 2023-03-22
AU2018238540A1 (en) 2019-11-07
JP2020514386A (ja) 2020-05-21
CN110662767A (zh) 2020-01-07
KR20190131068A (ko) 2019-11-25
US20240207397A1 (en) 2024-06-27

Similar Documents

Publication Publication Date Title
JP5926162B2 (ja) 炎症傷害の処置および評価
CA2670288C (en) Methods of treating chronic inflammatory diseases using a gm-csf antagonist
AU2007327993B2 (en) Methods of treating systemic lupus erythematosus
EP3237447B1 (en) Anti-csf1r antibodies for treating pvns
JP5905534B2 (ja) 多発性硬化症を治療する方法
JP2008544960A5 (https=)
KR20200140400A (ko) 집락 자극 인자 1 수용체(csf1r)에 결합하는 항체로 질환을 치료하는 방법
JP2025087764A (ja) ヒト化抗ｃｘｃｒ５抗体を使用するループスの処置
US20150291689A1 (en) Compositions and Methods for Treating Rheumatoid Arthritis
US20210077619A1 (en) Treatment of lupus using humanized anti-cxcr5 antibodies
US20250276059A1 (en) Therapeutic methods and agents for the treatment of myocardial infarction
WO2016118921A1 (en) Compositions and methods for treating psoriatic arthritis
CN121909046A (zh) 脱发病症的治疗
CN119923276A (zh) 用于治疗患有中度至重度系统性红斑狼疮的患者的抗cd38抗体的皮下给药
EA040840B1 (ru) Антитела против csf1r для лечения pvns

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)